Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Buy
56
CCAP Quote, Financials, Valuation and Earnings
Last price:
$15.80
Seasonality move
:
7.16%
Day range:
$15.95 - $16.28
52-week range:
$13.54 - $20.19
Dividend yield:
12.05%
P/E ratio:
8.14x
P/S ratio:
7.19x
P/B ratio:
0.81x
Volume:
63.6K
Avg. volume:
169.5K
1-year change:
-6.95%
Market cap:
$600M
Revenue:
$83.5M
EPS (TTM):
$1.99
Analysts' Opinion
-
Consensus RatingCrescent Capital BDC has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.08, Crescent Capital BDC has an estimated upside of 17.87% from its current price of $16.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 1.17% downside risk from its current price of $16.19.
Fair Value
-
According to the consensus of 4 analysts, Crescent Capital BDC has 17.87% upside to fair value with a price target of $19.08 per share.
CCAP vs. S&P 500
-
Over the past 5 trading days, Crescent Capital BDC has overperformed the S&P 500 by 3.49% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Crescent Capital BDC does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Crescent Capital BDC revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Crescent Capital BDC reported revenues of $12.4M.
Earnings Growth
-
Crescent Capital BDC earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Crescent Capital BDC reported earnings per share of $0.27.
Enterprise value:
1.5B
EV / Invested capital:
--
Price / LTM sales:
7.19x
EV / EBIT:
10.97x
EV / Revenue:
17.55x
PEG ratio (5yr expected):
0.11x
EV / Free cash flow:
24.88x
Price / Operating cash flow:
10.19x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
4.48%
Net Income Margin (TTM):
88.2%
Return On Equity:
9.86%
Return On Invested Capital:
4.59%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $23.2M | $92.5M | $83.5M | $33M | $12.4M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $0.49 | $2.30 | $1.99 | $0.84 | $0.27 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6M | $33.8M | $24.5M | $27.2M | $27.1M | |
| Total Assets | $1.1B | $1.3B | $1.3B | $1.6B | $1.7B | |
| Current Liabilities | $17.4M | $29M | $29M | $35.9M | $35.3M | |
| Total Liabilities | $494.2M | $665.5M | $690.3M | $884.8M | $915.6M | |
| Total Equity | $560M | $652.3M | $612.5M | $742.6M | $740.6M | |
| Total Debt | $471.9M | $631M | $654.5M | $844.8M | $875.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $28M | $92.3M | $58.9M | $34.6M | -$2.9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -$34.4M | -$85M | -$43.5M | -$33M | $5M | |
| Free Cash Flow | $28M | $92.3M | $58.9M | $34.6M | -$2.9M | |
CCAP
Sector
Market Cap
$600M
$603.7M
Price % of 52-Week High
80.19%
84.45%
Dividend Yield
12.05%
2.05%
Shareholder Yield
--
3.98%
1-Year Price Total Return
-6.95%
9.07%
Beta (5-Year)
0.567
0.555
Dividend yield:
12.05%
Annualized payout:
$2.04
Payout ratio:
102.15%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$15.77
200-day SMA
Sell
Level
$18.38
Bollinger Bands (100)
Sell
Level
16.62 - 19.86
Chaikin Money Flow
Sell
Level
-4.8M
20-day SMA
Buy
Level
$15.56
Relative Strength Index (RSI14)
Buy
Level
51.18
ADX Line
Sell
Level
36.47
Williams %R
Sell
Level
-10.473
50-day SMA
Sell
Level
$17.03
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
2.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.5929)
Sell
CA Score
(Annual)
Level (-0.3007)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (0.701)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
Stock Forecast FAQ
In the current month, CCAP has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CCAP average analyst price target in the past 3 months is $19.08.
-
Where Will Crescent Capital BDC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Crescent Capital BDC share price will rise to $19.08 per share over the next 12 months.
-
What Do Analysts Say About Crescent Capital BDC?
Analysts are divided on their view about Crescent Capital BDC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Crescent Capital BDC is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Crescent Capital BDC's Price Target?
The price target for Crescent Capital BDC over the next 1-year time period is forecast to be $19.08 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CCAP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Crescent Capital BDC is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CCAP?
You can purchase shares of Crescent Capital BDC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Crescent Capital BDC shares.
-
What Is The Crescent Capital BDC Share Price Today?
Crescent Capital BDC was last trading at $15.80 per share. This represents the most recent stock quote for Crescent Capital BDC. Yesterday, Crescent Capital BDC closed at $16.19 per share.
-
How To Buy Crescent Capital BDC Stock Online?
In order to purchase Crescent Capital BDC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 6.65% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 2.41% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 5.73% over the past day.
